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BACKGROUND TO THE STUDY
Benzodiazepines have anxiolytic, sedative, hypnotic and muscle relaxant effects and are used to 
treat anxiety, panic and sleep disorders.  They may result in an altered mental state, including 
euphoria, resulting in misuse and abuse.1 Misuse includes pharmacologic dependence, especially 
when used for more than one month.  Drugs with a shorter half-life are associated with more severe 
withdrawal symptoms and dependence2, although symptoms vary between patients.3
Abuse includes behaviour that accompanies psychological dependence4, and includes drug diversion 
for illicit purposes.  Legal restrictions on prescribing and dispensing limit misuse and abuse and 
in South Africa, benzodiazepines are Schedule 5 medicines.  Although the abuse potential of 
benzodiazepines is low2, alprazolam was  rescheduled from a prescription drug to a Controlled 
Drug in Australia in 2014 due to its potential for illicit drug use.5,6  Benzodiazepines used orally for 
recreational purposes include diazepam, alprazolam, temazepam, flunitrazepam and, to a lesser 
extent, triazolam and lorazepam.7
PRIMARY AIM
The primary aim of this pilot study was to investigate benzodiazepine prescribing patterns 
with a specific focus on cross-national comparative dispensing.
METHODOLOGY
}	 A retrospective, cross-sectional, cross-national comparative drug utilisation study was 
conducted on two datasets of prescriptions dispensed in 2010 and 2011.
}	 The South African database contained approximately 5 million records for medicines, 
medical devices and procedures, and was obtained from a medical insurance (medical aid) 
administrator in South Africa. 
}	 The Australian data consisted of de-identified dispensing data that was extracted from 
three pilot sites (pharmacies) in a metropolitan city in Australia.  This experimental dataset 
contained 1 311 669 dispensing records extracted over a 3-year period.  In Australia, most 
medicines required to treat common conditions are subsidised by the government and 
Australian permanent residents pay a levy towards the cost of the medicine, similar to 
the patient contribution of medical aid schemes in South Africa.  Data included dispensed 
prescriptions that were subsidised by the government as well as prescriptions for which 
patients paid the full amount.
}	 The Anatomical Therapeutic Chemical (ATC) Classification System8, MIMS9   and the South 
African Medicines Formulary10 were used to identify medicines.  For the South African data, 
all medication records for benzodiazepines and benzodiazepine-related drugs were extracted 
according to the MIMS classification system9.  The Australian Medicines Handbook11 and ATC 
were used to classify the Australian data.
}	 Each medication record contained a unique number that represented each de-identified 
dispensing record, the date of the prescription, detailed information on the dispensed drug 
(name, package size, formulation, strength and quantity).
}	 Microsoft Access® and Excel® were used to analyse the data.
}	 Ethical approval to conduct studies on prescription databases was obtained from the Research 
Ethics Committee (Human) of the Nelson Mandela Metropolitan University (ethics clearance 
number: H08-HEA-PHA-005), and the process to extract and de-identify data from three 
pilot sites in Australia received ethical approval from the University of Queensland (ethical 
clearance 2012000078).
Limitations of the study 
} South African database:  Only data of patients served by the private health care sector 
in South Africa were included in the study and no clinical information or diagnoses were 
available.
} Australian dataset:  Only data from three participating pharmacies were included in this 
pilot study.
RESULTS AND DISCUSSION
Demographic information of patients
South Africa:  In 2010 and 2011, a total of 71 390 prescriptions for benzodiazepines and benzodiaz-
epine-related drugs were dispensed to 16 601 patients.  In 2010, a total of 34 966 benzodiazepine 
prescriptions were dispensed to 9 606 patients (45.72% males) reflecting on average 3.64 benzodi-
azepine products per patient.  Prescribing frequency decreased marginally the following year to an 
average of 3.45 products per patient, with 36 424 benzodiazepines prescribed to 10 556 patients of 
which 40.44% were males.
Australia:  The dataset did not contain reliable gender information.  The surrogate marker for gen-
der was the title of the patient (mr/mrs/miss/ms/master) and indicated that 30.70% of anxiolytic, 
sedative and hypnotic prescriptions were dispensed to females and 21.32% to males;  however, 
gender was unknown for the remaining 52.02% of benzodiazepine prescriptions.  Date of birth was 
not extracted from the database for privacy reasons.
Active ingredients dispensed
In the South Africa dataset, benzodiazepines constituted 64.79% of prescriptions, sedative hypnotics 
(other) accounted for 29.17% and anxiolytics (other) for 6.04%.  In the Australian dataset there were 
1 311 669 dispensed prescriptions that were extracted in a 3-year period.  During 2010 and 2011, 
a total of 3 960 dispensing records were analysed for this study including the non-benzodaizepine 
hypnotics zolpidem (n=362) and zopiclone (42).  Clonazepam is indicated for epilepsy and was 
excluded from the study; 19 active ingredients are reported in Table 1.
TABLE 1
Comparative relative percentage frequency of active ingredients dispensed 2010 and 2011
ACTIVE 
INGREDIENTS
Half-life
% Australia 
/ 
South 
Africa data
Australian dataset  
% 
South African data 
%
2010
n=2030
2011
n=1930
Total
n=3960
2010
n=32775
2011
n=34579
Total
n=67354
Temazepam Short 21:1 24.51 25.28 24.89 1.12 1.20 1.16
Nitrazepam Long 9:1 6.76 7.16 6.96 0.88 0.68 0.77
Flunitrazepam Long 4:1 1.02 1.48 1.25 0.38 0.29 0.34
Oxazepam Short 3:1 18.73 15.81 17.31 6.13 4.84 5.47
Loprazolam Short 1:1 0 3.12 1.52 1.84 1.68 1.76
Alprazolam Short 1:2 7.98 8.24 8.10 17.45 16.39 16.91
Diazepam Long 1:2 25.24 27.53 26.36 17.85 14.88 16.33
Clobazam Long 1:3 1.02 0.97 1.00 2.88 3.86 3.38
Midazolam V.Short 1:7 0.29 0.20 0.25 1.89 1.59 1.74
Lorazepam Medium 1:5 1.65 0 0.85 4.33 4.13 4.23
Triazolam V.Short 0 0 0 0.40 0.32 0.36
Bromazepam Medium 1:65 0.10 0.31 0.20 9.35 16.23 12.88
Flurazepam Short - - - 0.01 0 0.01
Brotizolam Short - - - 0.03 0.02 0.02
Long - - - 0.01 0 0.02
Lormetazepam Short - - - 0.08 0.05 0.06
Prazepam Long - - - 0.10 0.06 0.08
OTHER
Zolpidem 1:2 9.87 8.14 0.03 17.77 17.71 17.74
Zopiclone 1:11 1.56 0.511 1.05 12.17 11.01 11.58
Cross-national comparison
In this exploratory comparative cross-national pilot the datasets were not directly comparable; 
therefore, we designed a method that permitted qualitative comparisons.  Comparative Relative 
Percentage Frequency was calculated by expressing the relative percentage frequency of dispensing 
in each dataset as a ratio of dispensed prescriptions from Australia:South Africa datasets.  Six active 
ingredients accounted for more than a four-fold difference in prescribing between the two countries: 
temazepam and nitrazepam were dispensed more frequently at the Australian pilot sites (21 times 
and nine times, respectively), while bromazepam, midzalom and lorazepam were dispensed more 
frequently in South Africa (65 times, seven, and five times, respectively).  Zolpidem was dispensed 
twice as frequently in South Africa compared to the Australian sites, while zopiclone was dispensed 
11 times more frequently (Figure 1).  Prazepam, brotizolam, flurazepam and chlordiazepoxide were 
not available or were not subsidised medicines in Australia at the time of the study.
 FIGURE 1
 Comparative Relative Percentage Frequency of benzodiazepine prescribing
Benzodiazepine prescribing according to half-life 
A visual comparison of the relative percentage frequencies of benzodiazepines dispensed in South 
Africa and in the Australian sites is shown in Figure 2, classified according to half-life as short half-
life is associated with withdrawal effects and hence dependence.2  There was a greater percentage 
of short or very short acting benzodiazepines in the Australian data (52.07%) compared to South 
African data (27.49 %). 
 FIGURE 2
 Relative percentage frequency of benzodiazepine prescriptions according to 
 half-life (n
Australia 
=3 960;  n
South Africa 
=67 354)
Benzodiazepine active ingredients
}	 Alprazolam
In the South African database, most (89.34%) prescriptions for alprazolam were prescribed 
in quantities of 14 or more tablets/capsules per prescription.  It was noteworthy that one 
South African patient (a 51 year old female) received 30 prescriptions for alprazolam 
during this period.  The prescriptions were, however, for a quantity of only ten 0.5 mg 
tablets per prescription, and the restricted quantity may have been an attempt to control 
the use.  Also of interest: in the Australian data, on two occasions a quantity exceeding 
120 tablets was dispensed.  Medicines are dispensed in fixed pack sizes and at the time of 
the study, alprazolam was available in packs of 50 tablets.  Alprazolam was rescheduled 
to a Controlled Drug in Australia in February 2014 due to concerns over misuse12 - in higher 
dosages and mixed with alcohol, alprazolam enhances the “high” feeling that the drug 
generates.
}	 Bromazepam
The medium-acting benzodiazepines bromazepam was dispensed 65 times more 
frequently in South Africa.  This is most likely due to restrictions on its use in Australia, 
as its subsidised use is limited to patients with terminal disease or refractory phobic or 
anxiety states.
}	 Temazepam
The short-acting temazepam was dispensed more than twenty times more frequently at 
the Australian experimental sites.  It is prescribed for short-term insomnia and is dispensed 
in packs containing 25 units.
}	 Diazepam
Diazepam was the most frequently dispensed benzodiazepine at the Australian sites and 
the third most frequently prescribed active ingredient in South Africa.  Although it has a 
longer half-life, diazepam has abuse potential due to its rapid onset of action.2
The findings support those of other studies:  in Cape Town, benzodiazepines are the most widely 
misused medicines in treatment centres 13 and were the primary substance of abuse among women,14 
and they are known to be subject to misuse in Australia.15
CONCLUSIONS AND RECOMMENDATIONS
}	 There are differences in benzodiazepine dispensing patterns between South African 
data and data from the experimental Australian sites;  these differences may have 
been influenced by local administrative, financial or therapeutic  restrictions.
}	 Benzodiazepine prescribing may influence intentional and unintentional misuse and, 
ultimately, abuse.  Although overuse is difficult to prove in studies conducted on 
databases, medicines usage studies are an important tool that can be used to monitor 
for potential misuse.
}	 Studies in cross-national trends may play a role in identifying potential drug misuse 
and future comparative studies with Australia and other countries may yield important 
results.  The length of therapy, dosages and, where possible, indication for use are 
aspects that could be investigated.
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